Osteoarthritis, Post-Traumatic Arthritis, Proximal Humeral Fracture, Psoriatic Arthritis, Rheumatoid Arthritis
Conditions
Keywords
Trauma, Medical Device, Performance, Safety, Proximal Humeral Fracture
Brief summary
This study is a multicenter, prospective, non-randomized, non-controlled post-market clinical follow-up study. The primary objective of this study is to confirm the safety and performance of the A.L.P.S. Proximal Humerus Plating System applied in proximal humerus fracture treatment.
Detailed description
The A.L.P.S. Proximal Humerus Plating System was developed to provide another surgical option for proximal humerus fracture fixation. The aim of the A.L.P.S. Proximal Humerus Plating System is to provide increased fracture stability while simultaneously increasing range of motion and decreasing the likelihood of screw perforation. A minimum of 7 and maximum of 10 sites globally will be involved in this study. This number of clinical sites will allow for a better generalization of study data as well as allow for consistency to be developed across multiple regions. 135 implants will be included into the study. Each site will be allowed to enroll 27 humeri. Enrollment is competitive. All potential study subjects will be required to participate in the Informed Consent process.
Interventions
DEVICEA.L.P.S. Proximal Humerus Plating System
Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.
Sponsors
Zimmer Biomet
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient must be 18 years of age or older. * Patient must have a primary proximal humerus fracture (Orthopaedic Trauma Association/ American Orthopedic 11-A, B, C) requiring surgical intervention and be eligible for fixation by plate and screws. * Patients with failed conservative treatment within 3 weeks since injury. * Patient must be able and willing to complete the protocol required follow-up. * Patient must have a signed Institutional Review Board/Ethics Committee approved informed consent. * Patient must be in a good nutritional state
Exclusion criteria
* Delay of surgery for more than 3 weeks. * Tumor induced fractures * Patient is a prisoner. * Pregnancy/ breast feeding * Patient is a current alcohol or drug abuser. * Patient has a mental or neurologic condition that will not allow for proper informed consent and/or participation in follow-up program. * Patient has an active infection. * Patient conditions including limitations in blood supply, obesity, or insufficient quantity or quality of bone stock. * Patient is sensitive to foreign body material.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Re-operation | 1 year | Re--operation within the first year post-initial surgery due to screw perforation of the humeral head, secondary displacement or impingement to relieve pain and/or improve function. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeon Patient Questionnaire | 2 years | Pain, function and activities of daily living are measured. The American Shoulder and Elbow Surgeon (ASES) scale is 0 to 100. 100 is the highest score and indicates the greatest function while 0 is the lowest score. |
| Shoulder range of motion measurement | 2 years | Shoulder range of motion is assessed in degrees of directional movement. This will be measured during a physical exam by the investigator. Values measured include active and passive range of motion. |
| Clinical performance of the device is assessed using x-ray capture | 2 years | X-ray capture will be used to analyze fracture healing |
Countries
Australia, Canada, South Korea, Switzerland, United States
Outcome results
None listed